Cargando…

Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO

BACKGROUND: The rational design of peptide-based specific inhibitors of the caspase family members using their X-ray crystallographies is an important strategy for chemical knockdown to define the critical role of each enzyme in apoptosis and inflammation. Recently, we designed a novel potent peptid...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimori, Atsushi, Sakai, Junichi, Sunaga, Satoshi, Kobayashi, Takanobu, Takahashi, Satoshi, Okita, Naoyuki, Takasawa, Ryoko, Tanuma, Sei-ichi
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1931592/
https://www.ncbi.nlm.nih.gov/pubmed/17594508
http://dx.doi.org/10.1186/1471-2210-7-8
_version_ 1782134284558008320
author Yoshimori, Atsushi
Sakai, Junichi
Sunaga, Satoshi
Kobayashi, Takanobu
Takahashi, Satoshi
Okita, Naoyuki
Takasawa, Ryoko
Tanuma, Sei-ichi
author_facet Yoshimori, Atsushi
Sakai, Junichi
Sunaga, Satoshi
Kobayashi, Takanobu
Takahashi, Satoshi
Okita, Naoyuki
Takasawa, Ryoko
Tanuma, Sei-ichi
author_sort Yoshimori, Atsushi
collection PubMed
description BACKGROUND: The rational design of peptide-based specific inhibitors of the caspase family members using their X-ray crystallographies is an important strategy for chemical knockdown to define the critical role of each enzyme in apoptosis and inflammation. Recently, we designed a novel potent peptide inhibitor, Ac-DNLD-CHO, for caspase-3 using a new computational screening system named the Amino acid Positional Fitness (APF) method (BMC Pharmacol. 2004, 4:7). Here, we report the specificity of the DNLD sequence against caspase-3 over other major caspase family members that participate in apoptosis by computational docking and site-directed mutagenesis studies. RESULTS: Ac-DNLD-CHO inhibits caspases-3, -7, -8, and -9 activities with K(i)(app )values of 0.68, 55.7, >200, and >200 nM, respectively. In contrast, a well-known caspase-3 inhibitor, Ac-DEVD-CHO, inhibits all these caspases with similar K(i)(app )values. The selective recognition of a DNLD sequence by caspase-3 was confirmed by substrate preference studies using fluorometric methylcoumarin-amide (MCA)-fused peptide substrates. The bases for its selectivity and potency were assessed on a notable interaction between the substrate Asn (N) and the caspase-3 residue Ser209 in the S(3 )subsite and the tight interaction between the substrate Leu (L) and the caspase-3 hydrophobic S(2 )subsite, respectively, in computational docking studies. Expectedly, the substitution of Ser209 with alanine resulted in loss of the cleavage activity on Ac-DNLD-MCA and had virtually no effect on cleaving Ac-DEVD-MCA. These findings suggest that N and L residues in Ac-DNLD-CHO are the determinants for the selective and potent inhibitory activity against caspase-3. CONCLUSION: On the basis of our results, we conclude that Ac-DNLD-CHO is a reliable, potent and selective inhibitor of caspase-3. The specific inhibitory effect on caspase-3 suggests that this inhibitor could become an important tool for investigations of the biological function of caspase-3. Furthermore, Ac-DNLD-CHO may be an attractive lead compound to generate novel effective non-peptidic pharmaceuticals for caspase-mediated apoptosis diseases, such as neurodegenerative disorders and viral infection diseases.
format Text
id pubmed-1931592
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-19315922007-07-25 Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO Yoshimori, Atsushi Sakai, Junichi Sunaga, Satoshi Kobayashi, Takanobu Takahashi, Satoshi Okita, Naoyuki Takasawa, Ryoko Tanuma, Sei-ichi BMC Pharmacol Research Article BACKGROUND: The rational design of peptide-based specific inhibitors of the caspase family members using their X-ray crystallographies is an important strategy for chemical knockdown to define the critical role of each enzyme in apoptosis and inflammation. Recently, we designed a novel potent peptide inhibitor, Ac-DNLD-CHO, for caspase-3 using a new computational screening system named the Amino acid Positional Fitness (APF) method (BMC Pharmacol. 2004, 4:7). Here, we report the specificity of the DNLD sequence against caspase-3 over other major caspase family members that participate in apoptosis by computational docking and site-directed mutagenesis studies. RESULTS: Ac-DNLD-CHO inhibits caspases-3, -7, -8, and -9 activities with K(i)(app )values of 0.68, 55.7, >200, and >200 nM, respectively. In contrast, a well-known caspase-3 inhibitor, Ac-DEVD-CHO, inhibits all these caspases with similar K(i)(app )values. The selective recognition of a DNLD sequence by caspase-3 was confirmed by substrate preference studies using fluorometric methylcoumarin-amide (MCA)-fused peptide substrates. The bases for its selectivity and potency were assessed on a notable interaction between the substrate Asn (N) and the caspase-3 residue Ser209 in the S(3 )subsite and the tight interaction between the substrate Leu (L) and the caspase-3 hydrophobic S(2 )subsite, respectively, in computational docking studies. Expectedly, the substitution of Ser209 with alanine resulted in loss of the cleavage activity on Ac-DNLD-MCA and had virtually no effect on cleaving Ac-DEVD-MCA. These findings suggest that N and L residues in Ac-DNLD-CHO are the determinants for the selective and potent inhibitory activity against caspase-3. CONCLUSION: On the basis of our results, we conclude that Ac-DNLD-CHO is a reliable, potent and selective inhibitor of caspase-3. The specific inhibitory effect on caspase-3 suggests that this inhibitor could become an important tool for investigations of the biological function of caspase-3. Furthermore, Ac-DNLD-CHO may be an attractive lead compound to generate novel effective non-peptidic pharmaceuticals for caspase-mediated apoptosis diseases, such as neurodegenerative disorders and viral infection diseases. BioMed Central 2007-06-27 /pmc/articles/PMC1931592/ /pubmed/17594508 http://dx.doi.org/10.1186/1471-2210-7-8 Text en Copyright © 2007 Yoshimori et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Yoshimori, Atsushi
Sakai, Junichi
Sunaga, Satoshi
Kobayashi, Takanobu
Takahashi, Satoshi
Okita, Naoyuki
Takasawa, Ryoko
Tanuma, Sei-ichi
Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO
title Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO
title_full Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO
title_fullStr Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO
title_full_unstemmed Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO
title_short Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO
title_sort structural and functional definition of the specificity of a novel caspase-3 inhibitor, ac-dnld-cho
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1931592/
https://www.ncbi.nlm.nih.gov/pubmed/17594508
http://dx.doi.org/10.1186/1471-2210-7-8
work_keys_str_mv AT yoshimoriatsushi structuralandfunctionaldefinitionofthespecificityofanovelcaspase3inhibitoracdnldcho
AT sakaijunichi structuralandfunctionaldefinitionofthespecificityofanovelcaspase3inhibitoracdnldcho
AT sunagasatoshi structuralandfunctionaldefinitionofthespecificityofanovelcaspase3inhibitoracdnldcho
AT kobayashitakanobu structuralandfunctionaldefinitionofthespecificityofanovelcaspase3inhibitoracdnldcho
AT takahashisatoshi structuralandfunctionaldefinitionofthespecificityofanovelcaspase3inhibitoracdnldcho
AT okitanaoyuki structuralandfunctionaldefinitionofthespecificityofanovelcaspase3inhibitoracdnldcho
AT takasawaryoko structuralandfunctionaldefinitionofthespecificityofanovelcaspase3inhibitoracdnldcho
AT tanumaseiichi structuralandfunctionaldefinitionofthespecificityofanovelcaspase3inhibitoracdnldcho